Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A protein from tumors may show up in blood — a trial puts the idea to the test

NCT ID NCT06068257

Diagnosis Sponsor: University of Central Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study investigates whether a protein called FGF19, normally found in the intestine and gallbladder, appears at higher levels in the blood of people with breast or colorectal cancer compared to healthy individuals. Researchers will measure FGF19 and related markers in fasting blood samples from about 119 adults — including cancer patients and healthy controls — to see if it could serve as a cancer detection biomarker. The goal is to establish whether tumors actively release FGF19 into the bloodstream and whether blood levels can distinguish people with cancer from those without.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test for FGF19 protein levels
What this could lead to
If successful, this could lead to a simple blood test to help detect breast or colorectal cancer earlier.
What could go wrong
This is an early-stage study to establish whether FGF19 levels differ between groups. It may not prove useful as a reliable screening tool, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

119 people

The number who actually took part.

Started

Jun 2023

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants currently diagnosed with breast cancer and colorectal cancer, as well as, healthy participants who are currently cancer-free.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw. (Pregnant women may choose to be in the study. The study procedures do not pose a risk to the safety of the unborn child or the woman.) Exclusion Criteria: * The study will not enroll persons who are unable or unwilling to provide informed consent. * Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colorectal cancer Healthy

Contacts and locations

Locations

  • Burnett School Biomedical Sciences

    Orlando, Florida, 32816, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.